Floatz logo

Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer

Metastatic Carcinoma

Explore 2 assets in Metastatic Carcinoma →
Floatz Rating
CCC52/100
Confidence
Indicative
v0.2
Sponsor
City of Hope Medical Center
Modality
monoclonal_antibody
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT03005002CT.gov
Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver
—Completed———
NCT02754856CT.gov
Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery
—Completed———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Metastatic Carcinoma

AssetSponsorPhaseRating
Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer (this asset)City of Hope Medical CenterP1CCC · 52
Interferon Alfa-2BRoswell Park Cancer InstituteP2B
CelecoxibRoswell Park Cancer InstituteP2B
NedaplatinZhejiang Cancer HospitalP2CCC
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, DimerCity of Hope Medical CenterP2CCC
IpilimumabM.D. Anderson Cancer CenterP1/2CCC
DurvalumabCity of Hope Medical CenterP1CCC
Bms 986156M.D. Anderson Cancer CenterP1/2CCC
NivolumabM.D. Anderson Cancer CenterP1/2CCC

+3 more in the Metastatic Carcinoma cohort

Other indications for Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer

IndicationSponsorPhaseRating
Malignant Pancreatic Neoplasm—P2BB · 68
Biliary Tract Neoplasm—P2BB · 66
Pancreatic Ductal Adenocarcinoma—P2BB · 66

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer in Metastatic Carcinoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/immunoglobulin-g2-anti-human-ctla-4-antigen-human-monoclonal-cp-675206-clone-1121-heavy-chain-disulphide-with-human-monoclonal-cp-675206-clone-1121-light-chain-dimer-metastatic-carcinoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →